MANNEDORF, Switzerland and AUSTIN, Texas, Oct. 12 /PRNewswire-FirstCall/ -- The Tecan Group (SIX Swiss Exchange: TECN) and Luminex Corporation (Nasdaq: LMNX) have announced that they will collaborate on the development of a new automated newborn screening solution that will provide faster results for infants' potential health concerns. The companies have entered into a global OEM agreement that allows them to combine Luminex® xMAP® technology and LX 200™ instrument with Tecan's flexible and reliable Freedom EVO® liquid handling platform and HydroFlex™ washer. The new automated newborn screening solution will help laboratories enhance efficiency, save vital resources and analyze more samples more quickly. Luminex expects to launch the automated newborn screening solution in 2011.
Thomas Bachmann, CEO of Tecan, said: "We are delighted that we have been chosen by Luminex to supply a fully automated solution for such an important application. This global OEM agreement is building on a long, well established partnership of creating the most advanced automated solutions in the research market for Luminex xMAP technology."
Luminex xMAP technology enables large numbers of biological tests to be conducted simultaneously and analyzed quickly, cost-effectively and accurately. Once it receives regulatory clearance, NeoPlex4™ will be a fully automated, walk-away testing platform for multiplexed newborn screening. These high-volume screening assays test newborn infants for several different biomarkers linked to critical diseases. Each of these conditions can cause severe mental and physical disability if untreated. If detected early through testing, effective treatment can be initiated. Multiplexing these tests together from one sample offers significant improvements in testing efficiency.
Patrick Balthrop, CEO of Luminex, said: "Automation continues to be a top priority for Luminex and our customers. The high testing volumes in the newborn screening market require full sample-to-answer automation for the thousands of specimens processed by each customer per day. We evaluated several different robotic solutions to achieve this full automation for our xMAP technology and determined that Tecan was the best option available for this application. We have had a very effective relationship with Tecan and we are proud to be partnered with them in this effort."
About TecanTecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).
About Luminex CorporationLuminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.For further information:Tecan GroupMartin BraendleHead of Corporate Communications & Investor RelationsTel. +41 (0) 44 922 84 30Fax +41 (0) 44 922 88 firstname.lastname@example.orgLuminex Contacts:Luminex Corporate Contact:Harriss T. Currie, Vice President, Finance and Chief Financial Officer512.219.8020Matthew ScaloSr. Director Investor Relations512.email@example.comLuminex Media Contact:Aaron DeLucia512.firstname.lastname@example.org
Related medicine technology :1
|SOURCE Luminex Corporation; The Tecan Group|
Copyright©2010 PR Newswire.
All rights reserved
. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference2
. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer3
. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models4
. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer5
. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)6
. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)7
. NEXUS Biosystems Acquires Tecan Groups REMP Sample Management Business8
. NEXUS Biosystems Completes Acquisition of REMP Sample Management Business From Tecan Group9
. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease10
. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership11
. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery